Mirati Therapeut Stock Price, News & Analysis

Mirati Therapeutics, Inc. (NASDAQ: MRTX) announced its participation in two major healthcare conferences. The first is on February 9 at 12:30 p.m. ET during the Guggenheim Healthcare Talks: Oncology Conference, featuring James Christensen, Ph.D., as the speaker. The second conference is on February 18 at 12:00 p.m. ET at the SVB Leerink 2022 Global Healthcare Conference, with David Meek as the representative. Investors can access live webcasts on Mirati's website.

On January 21, 2022, Mirati Therapeutics (NASDAQ: MRTX) announced positive results from a Phase 2 cohort of the KRYSTAL-1 study. The study evaluated adagrasib at a 600mg BID dose in patients with KRAS^G12C-mutated gastrointestinal tumors, including pancreatic cancer. Key findings included a 41% objective response rate (ORR) in evaluable patients and a 100% disease control rate (DCR). The median progression-free survival (mPFS) was 6.6 months for pancreatic cancer patients. The drug was well tolerated, with manageable side effects, suggesting its potential as a viable treatment option.

Mirati Therapeutics (NASDAQ: MRTX) will present at the J.P. Morgan 40th Annual Virtual Healthcare Conference on January 10, 2022, at 2:15 p.m. PT / 5:15 p.m. ET. CEO David Meek will share insights about the company and its drug development pipeline, including adagrasib (MRTX849) and sitravatinib. Investors can access the live webcast on Mirati.com, with a replay available afterward. Mirati focuses on transformative cancer therapies, targeting unmet needs in oncology.

Mirati Therapeutics, Inc. (NASDAQ: MRTX) will participate in a fireside chat at the Evercore ISI HealthCONx Conference on December 2 at 11:15 a.m. P.T.. The company will be represented by CEO David Meek and Charles Baum, M.D., Ph.D.. The webcast will be accessible via Mirati's website after the event.

Mirati Therapeutics and Verastem Oncology announced a clinical collaboration to assess the combination of Mirati's adagrasib, a KRAS^G12C inhibitor, with Verastem's VS-6766, a RAF/MEK inhibitor, in treating KRAS^G12C-mutant non-small cell lung cancer (NSCLC). This multi-center trial aims to evaluate the maximum tolerated and recommended doses, alongside safety and efficacy in patients resistant to existing treatments. Both companies are optimistic about improved outcomes for patients facing high unmet needs in NSCLC.

Mirati Therapeutics (Nasdaq:MRTX) and Verastem Oncology (Nasdaq:VSTM) announced a collaboration to evaluate the combination of Mirati's adagrasib and Verastem's VS-6766 in treating KRAS^G12C-mutant non-small cell lung cancer (NSCLC). The Phase 1/2 trial aims to determine the maximum tolerated dose and assess safety and efficacy in patients who have progressed on a KRAS^G12C inhibitor. The collaboration targets unmet needs in NSCLC treatments, potentially enhancing patient outcomes.

Mirati Therapeutics (NASDAQ: MRTX) has submitted an Investigational New Drug (IND) application to the FDA for MRTX1719, a PRMT5 inhibitor targeting methylthioadenosine phosphoylase (MTAP)-deleted cancers. Preclinical studies indicate that MRTX1719 selectively inhibits tumor cells with MTAP deletions, which occur in about 10% of cancers, including pancreatic and lung cancers. A Phase 1/2 clinical trial is planned for Q1 2022, pending FDA clearance. This marks a significant step in advancing Mirati's oncology pipeline and reinforces its commitment to innovative cancer therapies.

Mirati Therapeutics, Inc. (Nasdaq: MRTX) has priced a public offering of 3,448,275 shares of common stock at $145.00 per share, raising approximately $500 million in gross proceeds. The offering is set to close on November 15, 2021, pending customary conditions, with underwriters granted a 30-day option to purchase an additional 517,241 shares. Proceeds will fund the U.S. commercial launch of adagrasib for KRAS G12C-mutated non-small cell lung cancer, ongoing clinical development, and working capital. Goldman Sachs, SVB Leerink, and Cowen act as book-running managers.

On November 9, 2021, Mirati Therapeutics (Nasdaq: MRTX) announced a proposed underwritten public offering of $500 million in common stock. The underwriters may purchase an additional 15% of shares within 30 days of the offering. The company has filed a shelf registration statement with the SEC. No assurance is given regarding the timing or completion of the offering. Goldman Sachs, SVB Leerink, and Cowen are managing the offering. The offering aims to fund developments in cancer therapeutics, including investigational drugs targeting KRAS mutations.